This will be the first MEVION S250i Proton Therapy System in the
Asia-Pacific Region.

Mevion Medical Systems announced today it has signed a contract with Allcure
Kangtai Proton Technology Co., Ltd. in China for the purchase of a
MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning
technology in late December. This was the fourth system sold by Mevion
in 2018 and the first sale by Mevion in the Asia-Pacific region.

As the global leader in compact proton therapy systems, Mevion was the
first company to innovate this new approach to proton therapy and
continues to transform the industry and patient care with HYPERSCAN
Pencil Beam Scanning.

Cleared by the FDA in 2017, HYPERSCAN improves on existing scanning
capabilities to deliver conformal fields of therapeutic radiation
therapy to tumors faster and with more precision.

“Mevion is proud to partner with Allcure Kangtai to deliver advanced
proton therapy systems for Chinese cancer patients,” said Tina Yu, CEO
of Mevion Medical Systems. “Our proton systems have been installed and
are treating patients in leading cancer centers in Europe and the U.S.
Today, nearly 80 percent of active single-room compact proton centers in
the U.S. use Mevion systems. We look forward to becoming the preferred
partner for leading cancer centers in the Asia-Pacific region as well.”

About Mevion Medical Systems
Mevion
Medical Systems, Inc. is the leading provider of compact proton therapy
systems for use in radiation treatment for cancer patients. Mevion is
based in Littleton, Massachusetts, with a presence in Europe and China.
For more information, please visit www.mevion.com.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.